Escherichia coli resistente a la fosfomicina: un hecho que nos invita a reflexionar sobre la resistencia bacteriana

  • Jaime Alberto López Vargas Laboratorio Clínico Hematológico
  • Germán Campuzano Maya Laboratorio Clínico Hematológico
Palabras clave: farmacorresistencia bacteriana, resistencia beta-lactámica, Escherichia coli uropatogénica, antibacterianos.

Resumen

La resistencia bacteriana es un problema de salud pública que dificulta cada vez más el tratamiento de los pacientes con infecciones del tracto urinario o de otros sistemas. Si bien los casos de resistencia estaban restringidos al entorno hospitalario, en la actualidad son más comunes las infecciones adquiridas en la comunidad causadas por bacterias multirresistentes. En este artículo se presenta una reflexión acerca del riesgo que representa la multirresistencia, y el surgimiento de resistencia a las alternativas terapéuticas para el tratamiento exitoso de las infecciones de tracto urinario, así como se reflexiona sobre puntos clave relacionados con el uso adecuado de las pruebas diagnósticas y los antibióticos en este tipo de infecciones.

Descargas

La descarga de datos todavía no está disponible.

Biografía del autor/a

Jaime Alberto López Vargas, Laboratorio Clínico Hematológico

Médico especialista en Microbiología y Parasitología Médicas. Coordinador sección de Microbiología. Laboratorio Clínico Hematológico. Medellín, Colombia.

Germán Campuzano Maya, Laboratorio Clínico Hematológico

Médico especialista en Hematología y Patología Clínica. Docente, Ad Honorem, Facultad de Medicina, Universidad de Antioquia. Médico Director, Laboratorio Clínico Hematológico. Medellín, Colombia.

Citas

Savard P, Perl TM. A call for action: managing the emergence of multidrug-resistant Enterobacteriaceae in the acute care settings. Curr Opin Infect Dis 2012; 25: 371-377.

https://doi.org/10.1097/QCO.0b013e3283558c17

Amábile-Cuevas CF. Global perspectives of antibiotic resistance In: J. SA, Byarugaba DK, Amábile-Cuevas CF, Hsueh P, Kariuki S, Okeke IN, eds. Antimicrobial Resistance in Developing Countries. New York: Springer; 2010.

https://doi.org/10.1007/978-0-387-89370-9_1

Pitout JD. Enterobacteriaceae that produce extended-spectrum beta-lactamases and AmpC beta-lactamases in the community: the tip of the iceberg? Curr Pharm Des 2013; 19: 257-263.

https://doi.org/10.2174/138161213804070348

Salvatore S, Cattoni E, Siesto G, Serati M, Sorice P, Torella M. Urinary tract infections in women. Eur J Obstet Gynecol Reprod Biol 2011; 156: 131-136.

https://doi.org/10.1016/j.ejogrb.2011.01.028

McCarter YS, Burd EM, Hall GS, Zervos M. Laboratory Diagnosis of Urinary Tract Infections. Coordinating ed., S. E. Sharp. ASM Press, Washington, DC. 2009; Cumitech 2C, .

Ronald A. The etiology of urinary tract infection: traditional and emerging pathogens. Am J Med 2002; 113 Suppl 1A: 14S-19S.

https://doi.org/10.1016/S0002-9343(02)01055-0

Carlet J, Jarlier V, Harbarth S, Voss A, Goossens H, Pittet D. Ready for a world without antibiotics? The Pensieres Antibiotic Resistance Call to Action. Antimicrob Resist Infect Control 2012; 1: 11.

https://doi.org/10.1186/2047-2994-1-11

Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011; 52: e103-120.

https://doi.org/10.1093/cid/ciq257

Bours PH, Polak R, Hoepelman AI, Delgado E, Jarquin A, Matute AJ. Increasing resistance in community-acquired urinary tract infections in Latin America, five years after the implementation of national therapeutic guidelines. Int J Infect Dis 2010; 14: e770-774.

https://doi.org/10.1016/j.ijid.2010.02.2264

Leal AL, Cortes JA, Arias G, Ovalle MV, Saavedra SY, Buitrago G, et al. Emergencia de fenotipos resistentes a cefalosporinas de tercera generacion en Enterobacteriaceae causantes de infeccion del tracto urinario de inicio comunitario en hospitales de Colombia. Enferm Infecc Microbiol Clin 2012.

https://doi.org/10.1016/j.eimc.2012.04.007

Grupo de Estudio de Resistencia de Medellín (GERMEN). http://www.grupogermen.org/pdf/escherichia.pdf Consultado en abril de 2013

Auer S, Wojna A, Hell M. Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli. Antimicrob Agents Chemother 2010; 54: 4006-4008.

https://doi.org/10.1128/AAC.01760-09

McKinnell JA, Stollenwerk NS, Jung CW, Miller LG. Nitrofurantoin compares favorably to recommended agents as empirical treatment of uncomplicated urinary tract infections in a decision and cost analysis. Mayo Clin Proc 2011; 86: 480-488.

https://doi.org/10.4065/mcp.2010.0800

Carlet J, Mainardi JL. Antibacterial agents: back to the future? Can we live with only colistin, co-trimoxazole and fosfomycin? Clin Microbiol Infect 2012; 18: 1-3.

https://doi.org/10.1111/j.1469-0691.2011.03702.x

Gobernado M. Fosfomicina. Rev Esp Quimioterap 2003; 16: 15-40.

Kahlmeter G, Poulsen HO. Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO.SENS study revisited. Int J Antimicrob Agents 2012; 39: 45-51.

https://doi.org/10.1016/j.ijantimicag.2011.09.013

Naber KG, Schito G, Botto H, Palou J, Mazzei T. Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. Eur Urol 2008; 54: 1164-1175.

https://doi.org/10.1016/j.eururo.2008.05.010

Falagas ME, Vouloumanou EK, Togias AG, Karadima M, Kapaskelis AM, Rafailidis PI, et al. Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials. J Antimicrob Chemother 2010; 65: 1862-1877.

https://doi.org/10.1093/jac/dkq237

Palou J, Angulo JC, Ramon de Fata F, Garcia-Tello A, Gonzalez-Enguita C, Boada A, et al. Randomized Comparative Study for the Assessment of a New Therapeutic Schedule of Fosfomycin Trometamol in Postmenopausal Women with Uncomplicated Lower Urinary Tract Infection. Actas Urol Esp 2013; 37: 147-155.

https://doi.org/10.1016/j.acuro.2012.06.007

Oteo J, Bautista V, Lara N, Cuevas O, Arroyo M, Fernández S, et al. Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli. J Antimicrob Chemother 2010; 65: 2459-2463.

https://doi.org/10.1093/jac/dkq346

Wachino J, Yamane K, Suzuki S, Kimura K, Arakawa Y. Prevalence of fosfomycin resistance among CTX-M-producing Escherichia coli clinical isolates in Japan and identification of novel plasmid-mediated fosfomycin-modifying enzymes. Antimicrob Agents Chemother 2010; 54: 3061-3064.

https://doi.org/10.1128/AAC.01834-09

He L, Partridge SR, Yang X, Hou J, Deng Y, Yao Q, et al. Complete nucleotide sequence of pHN7A8, an F33:A-:B-type epidemic plasmid carrying blaCTX-M-65, fosA3 and rmtB from China. J Antimicrob Chemother 2013; 68: 46-50.

https://doi.org/10.1093/jac/dks369

Lee SY, Park YJ, Yu JK, Jung S, Kim Y, Jeong SH, et al. Prevalence of acquired fosfomycin resistance among extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae clinical isolates in Korea and IS26-composite transposon surrounding fosA3. J Antimicrob Chemother 2012; 67: 2843-2847.

https://doi.org/10.1093/jac/dks319

Rodriguez-Avial C, Rodriguez-Avial I, Hernandez E, Picazo JJ. [Increasing prevalence of fosfomycin resistance in extended-spectrum-beta-lactamaseproducing Escherichia coli urinary isolates(2005-2009-2011)]. Rev Esp Quimioter 2013; 26: 43-46.

Wilson DT, May DB. Potential Role of Fosfomycin in the Treatment of Community-Acquired Lower Urinary Tract Infections Caused by Extended-Spectrum beta-Lactamase-Producing Escherichia coli. Am J Ther 2011.

Medina-Bombardo D, Jover-Palmer A. Does clinical examination aid in the diagnosis of urinary tract infections in women? A systematic review and meta-analysis. BMC Fam Pract 2011; 12: 111.

https://doi.org/10.1186/1471-2296-12-111

Mishra B, Srivastava S, Singh K, Pandey A, Agarwal J. Symptom-based diagnosis of urinary tract infection in women: are we over-prescribing antibiotics? Int J Clin Pract 2012; 66: 493-498.

https://doi.org/10.1111/j.1742-1241.2012.02906.x

Raz R. Asymptomatic bacteriuria. Clinical significance and management. Int J Antimicrob Agents 2003; 22 Suppl 2: 45-47.

https://doi.org/10.1016/S0924-8579(03)00248-6

Johnson JD, O'Mara HM, Durtschi HF, Kopjar B. Do urine cultures for urinary tract infections decrease follow-up visits? J Am Board Fam Med 2011; 24: 647-655.

https://doi.org/10.3122/jabfm.2011.06.100299

File TM, Jr., Solomkin JS, Cosgrove SE. Strategies for improving antimicrobial use and the role of antimicrobial stewardship programs. Clin Infect Dis 2011; 53 Suppl 1: S15-22.

https://doi.org/10.1093/cid/cir364

Duchene E, Montassier E, Boutoille D, Caillon J, Potel G, Batard E. Why is antimicrobial de-escalation under-prescribed for urinary tract infections? Infection 2013; 41: 211-214.

https://doi.org/10.1007/s15010-012-0359-x

McNulty CA, Lasseter GM, Charlett A, Lovering A, Howell-Jones R, Macgowan A, et al. Does laboratory antibiotic susceptibility reporting influence primary care prescribing in urinary tract infection and other infections? J Antimicrob Chemother 2011; 66: 1396-1404.

https://doi.org/10.1093/jac/dkr088

Cómo citar
1.
López Vargas JA, Campuzano Maya G. Escherichia coli resistente a la fosfomicina: un hecho que nos invita a reflexionar sobre la resistencia bacteriana. Med. Lab. [Internet]. 1 de marzo de 2013 [citado 2 de junio de 2020];19(3-4):183-8. Disponible en: https://medicinaylaboratorio.com/index.php/myl/article/view/223
Publicado
2013-03-01
Sección
Artículos de reflexión